DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Illumina)

ABSTRACT: Genome-scale measurements of DNA methylation levels are necessary to decipher the epigenetic events involved in glioblastoma aggressive phenotype, and to guide new therapeutic strategies. In that purpose, we performed a whole genome integrative analysis of the methylation and expression profiles for 40 newly diagnosed glioblastoma patients. We have also screened for associations between CpG sites methylation levels and overall survival in a cohort of 50 patients uniformly treated with radiotherapy and chemotherapy with concomitant and adjuvant temozolomide (STUPP protocol). The methylation analysis identified 616 CpG sites differentially methylated between glioblastoma and control brain, a quarter being differentially expressed in a concordant way. Among these concordant CpG sites, 13 gen

ORGANISM(S): Homo sapiens

SUBMITTER: Amandine Etcheverry 

PROVIDER: E-GEOD-22867 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress